论文部分内容阅读
目的回顾性分析初治的雌孕激素受体(ER/PR)及HER_2均阴性(简称“三阴”)的复发转移性乳腺癌的化疗疗效,寻求最佳一线化疗方案。方法311例初治的“三阴”性复发转移性乳腺癌患者采用一线化疗,96例患者采用AC(吡柔比星+环磷酰胺)方案,84例患者采用AT(吡柔比星+紫杉醇)方案,65例患者采用TC(紫杉醇+卡铂)方案,66例患者采用GT(吉西它滨+紫杉醇)方案,直至肿瘤进展。结果AC方案组总反应率(ORR)、中位疾病进展时间(mTTP)、中位总生存(mOS)均明显优于其他组,差异均有显著性(P<0.05),而AT组、TC组、GT组在ORR、mTTP、mOS方面均相似,差异均无显著性(P>0.05)。结论在初治的“三阴”性复发转移性乳腺癌患者中,AC方案是目前最有效的联合方案之一,一线治疗有效率高达87.5%,值得推荐。
Objective To retrospectively analyze the curative effect of primary and secondary estrogen and progesterone receptor (ER / PR) and HER2-negative (“Sanyin”) recurrent metastatic breast cancer to find the best first-line chemotherapy. Methods A total of 311 patients with newly diagnosed “Sanyin” recurrent metastatic breast cancer were treated with first-line chemotherapy, 96 patients were treated with AC (pirarubicin + cyclophosphamide), 84 patients were treated with AT (pirarubicin + Paclitaxel), 65 patients received TC (paclitaxel + carboplatin) and 66 patients received GT (gemcitabine + paclitaxel) until the tumor progressed. Results The total response rate (ORR), median disease progression time (mTTP) and median overall survival (mOS) in AC group were significantly higher than those in other groups (P <0.05) Group, GT group in ORR, mTTP, mOS aspects are similar, the difference was not significant (P> 0.05). Conclusion Among the newly diagnosed “triple negative” patients with recurrent metastatic breast cancer, the AC regimen is one of the most effective combination regimens currently. The effective rate of first-line treatment is as high as 87.5%, which is worth recommending.